Back

Dapagliflozin reduces epicardial adipose tissue in patients with heart failure with reduced ejection fraction and type 2 diabetes

1 September 2024 (12:00 - 12:50)
Organised by: Logo
Congress Presentation Part of: Myocardial ischaemia and heart failure: insight from multimodality imaging Imaging of Heart Failure ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Mohmmad Alghamdi

University of Dundee, Dundee (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
The role of semi-quantitative parameters of thallium-201 myocardial perfusion imaging in predicting mortality rate among CKD population
Doctor Y. Liu (Kaohsiung, TW)
Abstract Slides Video
Presentation thumbnail
Rosuvastatin effect on atherosclerotic plaque microcalcification
Doctor M. Santos (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Predictors of LV reverse remodeling after SAVR: insights from a prospective TTE and CMR study in patients with severe aortic stenosis.
Doctor R. Reis Santos (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
The correlation between cardiac magnetic resonance imaging and echocardiography in patients with severe ischaemic cardiomyopathy
Doctor T. Aklilu (London, GB)
Abstract Slides Video
Presentation thumbnail
Trend in culprit plaque phenotype in ACS patients over the past 10 years
Doctor K. Suzuki (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial ischaemia and heart failure: insight from multimodality imaging

The Event

Event poster

ESC Congress 2024

1 September 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Evaluation of tricuspid annular plane systolic excursion and epicardiac adipose tissue in patients with type 2 diabetes treated with oral semaglutide
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction: the CAMEO-DAPA randomized clinical trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources